China Licensing Deals
china_licensing_dealsBiotech and pharmaceutical licensing deals involving China — a Chinese company out-licensing a drug to a Western partner, or a Western company licensing rights INTO Greater China. Returns the two companies, the drug or asset, the territory, the upfront payment, milestone totals and royalty terms, with the SEC filing they were announced in and its date. Answers "which Chinese biotechs signed out-licensing deals", "recent China pharma licensing deals", "who licensed rights in Greater China". Sourced from SEC 8-K announcements, so it covers any deal with a US-listed party. Filter by company, drug name or date window.
Input Schema
| Name | Required | Description | Default |
|---|---|---|---|
| limit | No | Maximum deals to return, 1-40 (default 10). | |
| query | No | Optional extra term to narrow the search — a company ("Hengrui"), a drug ("VIZZ"), a modality ("ADC", "bispecific") or a therapy area ("oncology"). Combined with the deal and China terms, not replacing them. | |
| since | No | Earliest filing date (YYYY-MM-DD). Defaults to 90 days ago. | |
| until | No | Latest filing date (YYYY-MM-DD). Defaults to today. |